Methylphenidate and Parkinson's Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Parkinson's Disease

In brief

The purpose of this trial is to determine if methylphenidate (MPD), a drug marketed in the U.S. to treat hyperactivity and narcolepsy, added to levodopa, will increase the beneficial effects of levodopa without bothersome side effects in people with Parkinson's disease (PD).

Key facts

Study ID

NCT00359723

Run by

Oregon Health and Science University

People needed

13

Starts

2004-07-01

Expected to finish

2006-03-01

Last updated by the study team

2018-11-29

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Idiopathic PD treated with levodopa and experiencing motor fluctuations
• At least 21 years of age
• Male or female.

You may not qualify if…

• Cardiovascular disease, psychosis, extreme anxiety, dementia and other unstable medical conditions.

Where it is running

• Department of Neurology, OP-2, Oregon Health & Science University, 3181 SW Sam Jackson Park Road — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.